Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer

Genetic Testing and Molecular Biomarkers

Volumn 19, Issue 4, 2015, Pages 198-202

  Pan, Xin Min ^a   Sun, Rui Fen ^b   Li, Zhao Hui ^c   Guo, Xiao Min ^a   Qin, Hao Jie ^a   Gao, Lin Bo ^d  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b YUNNAN UNIVERSITY   (China)

^c ZHENGZHOU UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 34B; MICRORNA 34C; UNCLASSIFIED DRUG; MIRN34 MICRORNA, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH CANCER; AGED; CLINICAL TRIAL; GENETICS; MIDDLE AGED; STOMACH TUMOR;

ADULT; AGED; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84926619745     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2014.0287     Document Type: Article

References (42)

1. Bellini MF, Cadamuro AC, Succi M, et al. (2012) Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 34:1919-1923.
2. Belyi VA, Ak P, Markert E, et al. (2010) The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol 2:a001198.
3. Benchimol S, Lamb P, Crawford LV, et al. (1985) Transformation associated p53 protein is encoded by a gene on human chromosome 17. Somat Cell Mol Genet 11:505-510.
4. Cheng C, Lingyan W, Yi H, et al. (2014) Association between TLR2, MTR, MTRR, XPC, TP73, TP53 genetic polymorphisms and gastric cancer: a meta-analysis. Clin Res Hepatol Gastroenterol 38:346-359.
5. Corney DC, Flesken-Nikitin A, Godwin AK, et al. (2007) MicroRNA- 34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67:8433-8438.
6. Corney DC, Hwang CI, Matoso A, et al. et al. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16:1119-1128.
7. D'Elia L, Galletti F, Strazzullo P (2014) Dietary salt intake and risk of gastric cancer. Cancer Treat Res 159:83-95.
8. Dikshit RP, Mathur G, Mhatre S, Yeole BB (2011) Epidemiological review of gastric cancer in India. Indian J Med Paediatr Oncol 32:3-11.
9. Dumont P, Leu JI, Della Pietra AC 3rd, et al. (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365.
10. Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2011) Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer 129:920-930.
11. Gao LB, Li LJ, Pan XM, et al. (2013) A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem 394:415-420.
12. Gao LB, Rao L, Wang YY, et al. (2009) The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 30:295-299.
13. Han Y, Pu R, Han X, et al. (2013) Associations of pri-miR-34b/ c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One 8:e58564.
14. Hasegawa M, Nishiyama C, Nishiyama M, et al. (2003) A novel - 66T/C polymorphism in Fc epsilon RI alpha-chain promoter affecting the transcription activity: possible relationship to allergic diseases. J Immunol 171:1927-1933.
15. He C, Chen M, Liu J, Yuan Y (2014) Host genetic factors respond to pathogenic step-specific virulence factors of Helicobacter pylori in gastric carcinogenesis. Mutat Res Rev Mutat Res 759:14-26.
16. He X, He L, Hannon GJ (2007) The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67:11099-11101.
17. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17:193-199.
18. Ji Q, Hao X, Meng Y, et al. (2008) Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8:266.
19. Li L, Sima X, Bai P, et al. (2012) Interactions of miR-34b/c and TP53 polymorphisms on the risk of intracranial aneurysm. Clin Dev Immunol 2012:567586.
20. Li L, Wu J, Sima X, et al. (2013a). Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol 34:1919-1923.
21. Li ZH, Pan XM, Han BW, et al. (2013b). A let-7 binding site polymorphism rs712 in the KRAS 3D UTR is associated with an increased risk of gastric cancer. Tumour Biol 34:3159-3163.
22. Liang TJ, Liu HJ, Zhao XQ, et al. (2013) Lack of association of MiR-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis. PLoS One 8:e68588.
23. Matlashewski GJ, Tuck S, Pim D, et al. (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961-963.
24. Oh J, Kim JW, Lee BE, et al. (2014) Polymorphisms of the primiR- 34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. Oncol Rep 31:995-1002.
25. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108.
26. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9-29.
27. Son MS, Jang MJ, Jeon YJ, et al. (2013) Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene 524:156-160.
28. Soutto M, Chen Z, Saleh MA, et al. (2014) TFF1 activates p53 through down-regulation of miR-504 in gastric cancer. Oncotarget 5:5663-5673.
29. Tang W, Zhou X, Nie S, et al. (2012) Association of p53 Arg72Pro polymorphism with gastric cancer: a meta-analysis. Biomarkers 17:597-603.
30. Tian Q, Jia J, Ling S, et al. (2014) A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol 40:67-72.
31. Tsugane S (2005) Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci 96:1-6.
32. van Rietschoten JG, Westland R, van den Bogaard R, et al. (2004) A novel polymorphic GATA site in the human IL- 12Rbeta2 promoter region affects transcriptional activity. Tissue Antigens 63:538-546.
33. Wang AM, Huang TT, Hsu KW, et al. (2014) Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. Oncotarget 5:5002-5016.
34. Wang LG, Ni Y, Su BH, et al. (2013) MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol 42:957-962.
35. Wang XQ, Yan H, Terry PD, et al. (2012) Interaction between dietary factors and Helicobacter pylori infection in noncardia gastric cancer: a population-based case-control study in China. J Am Coll Nutr 31:375-384.
36. Xu Y, Liu L, Liu J, et al. (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128:412-417.
37. Yamakuchi M, Lowenstein CJ (2009) MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8:712-715.
38. Yin J, Wang X, Zheng L, et al. (2013) Hsa-miR-34b/c rs4938723 T > C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One 8:e80570.
39. Zhang J, Huang X, Xiao J, et al. (2014a). Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in chinese populations. PLoS One 9:e100055.
40. Zhang S, Qian J, Cao Q, et al. (2014b). A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis 29:149-154.
41. Zhao J, Lu Y, Shen HM (2012) Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett 314:8-23.
42. Zhou Y, Li N, Zhuang W, et al. (2007) P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121:1481-1486.